UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
December 6,2005
Date of Report (Date of earliest event reported)
ANTIGENICS INC
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-29089 06-1562417
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
630 Fifth Avenue, Suite 2100
New York, NY 10111 10111
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
212-994-8200
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.05 Costs Associated with Exit or Disposal Activities
On December 6, 2005, Antigenics Inc. issued a press release, attached
hereto as Exhibit 99.1, announcing an update to its business strategies and an
outline of the timeline for the analysis of its Phase 3 Kidney cancer trial. The
content of that press release is incorporated herein by reference.
As part of these strategies, the Company has terminated approximately
70 employees and has estimated its costs related to these terminations and other
related activities to be approximately $2 million including severance and other
cash costs.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated December 6, 2005
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ANTIGENICS INC.
Date: December 6, 2005
By: /s/ Garo H. Armen
-------------------------------------
Garo H. Armen, Ph.D.
Chairman and Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description of Exhibit
----------- ----------------------
99.1 Press Release dated December 6, 2005